Beta-hairpin peptidomimetics for selective elastase inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protease inhibitors lack selectivity and efficacy, particularly for serine proteases like human neutrophil elastase, and do not effectively mimic the extended β-strand conformation required for effective binding.
Innovation Solution
Development of β-hairpin peptidomimetics with specific amino acid residues and structural elements derived from β- and γ-amino acids, which are synthesized using combinatorial methods to achieve high inhibitory activity against human neutrophil elastase while minimizing activity against other proteases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional protease inhibitors are used, then inhibitory activity against proteases is achieved, but selectivity among different proteases is poor
Solution Approach 1:
The patent applies local quality by introducing specific amino acid residues at particular positions in the peptidomimetic sequence. Certain residues (e.g., hydrophobic residues at P1 position, basic residues at P2 position) are strategically placed to create local chemical features that selectively interact with human neutrophil elastase while avoiding interaction with other proteases like porcine pancreatic elastase and proteinase 3.
Solution Approach 2:
The patent employs parameter changes by modifying the conformational parameters of the peptidomimetic to adopt a β-hairpin structure with specific dimensions and flexibility. The cyclic backbone configuration and specific bond angles are optimized to match the binding pocket geometry of human neutrophil elastase, creating selective binding through geometric complementarity rather than general protease inhibition.
2Reliability
If peptidomimetics are designed to mimic extended β-strand conformation, then binding efficacy to proteases is improved, but structural complexity increases
Solution Approach 1:
The patent segments the peptidomimetic structure into distinct functional regions: a cyclic backbone providing structural framework, specific amino acid residues providing chemical recognition, and terminal groups providing binding functionality. This segmentation allows each component to be optimized independently for its specific function while maintaining overall simplicity.
Solution Approach 2:
The patent creates a composite peptidomimetic structure combining elements from different amino acid classes (α-amino acids, β-amino acids, and γ-amino acids) within a single cyclic framework. This composite approach leverages the structural advantages of each amino acid type to achieve the desired β-hairpin conformation while maintaining synthetic feasibility.
3Reliability
If selective amino acid residues are chosen for specific positions, then activity/selectivity profile is optimized, but synthesis complexity increases
Solution Approach 1:
The patent develops a universal synthesis approach using solid-phase peptide synthesis that can accommodate various amino acid residues at different positions. The same basic synthesis protocol works for all peptidomimetics in the series, with only the amino acid building blocks needing to be exchanged. This multi-functionality simplifies manufacturing by reducing the number of separate synthesis procedures required.
Solution Approach 2:
The patent employs preliminary action by pre-synthesizing and pre-purifying individual amino acid building blocks with specific configurations before incorporating them into the full peptidomimetic sequence. This allows for quality control and optimization of individual components before final assembly, reducing the need for complex purification steps during the overall synthesis process.
Data Source
AI summary
β-Hairpin peptidomimetics of the general formula cyclo(-Xaa1-Xaa2-Thr3-Xaa4-Ser5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-) and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and Xaa13 being amino acid residues of certain types which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.